Lyell Immunopharma, Inc. (NASDAQ:LYEL) CFO Acquires $112,000.00 in Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) CFO Charles W. Newton acquired 200,000 shares of Lyell Immunopharma stock in a transaction that occurred on Monday, March 17th. The stock was acquired at an average cost of $0.56 per share, for a total transaction of $112,000.00. Following the purchase, the chief financial officer now owns 200,000 shares of the company’s stock, valued at $112,000. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Lyell Immunopharma Stock Performance

Lyell Immunopharma stock opened at $0.53 on Friday. The firm has a 50 day moving average price of $0.61 and a two-hundred day moving average price of $0.89. Lyell Immunopharma, Inc. has a 52-week low of $0.48 and a 52-week high of $3.15. The firm has a market cap of $157.45 million, a price-to-earnings ratio of -0.68 and a beta of -0.41.

Lyell Immunopharma (NASDAQ:LYEL) last announced its earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The firm had revenue of $0.01 million for the quarter. As a group, equities research analysts predict that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Institutional Investors Weigh In On Lyell Immunopharma

Several institutional investors and hedge funds have recently made changes to their positions in LYEL. Centiva Capital LP acquired a new position in Lyell Immunopharma in the third quarter valued at approximately $31,000. Intech Investment Management LLC bought a new stake in shares of Lyell Immunopharma in the 3rd quarter valued at $52,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Lyell Immunopharma during the 3rd quarter valued at $52,000. Graham Capital Management L.P. bought a new position in Lyell Immunopharma during the fourth quarter worth $33,000. Finally, Erste Asset Management GmbH acquired a new stake in Lyell Immunopharma in the third quarter worth $82,000. Institutional investors own 66.05% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “neutral” rating and issued a $1.00 price target on shares of Lyell Immunopharma in a research report on Thursday, March 13th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.